Jan A. Burger, M.D., Ph.D.

Peer-Reviewed Articles

1. Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma 63(6):1-12, 2022. e-Pub 2022. PMID: 35014928.
2. Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia 36(5):1324-1335, 2022. e-Pub 2022. PMID: 35149845.
3. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia 36(3):712-722, 2022. e-Pub 2021. PMID: 34625713.
4. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
5. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. Blood 138(24):2589-2592, 2021. e-Pub 2021. PMID: 34521099.
6. Ferrer G, Jung B, Chiu PY, Aslam R, Palacios F, Mazzarello AN, Vergani S, Bagnara D, Chen SS, Yancopoulos S, Xochelli A, Yan XJ, Burger JA, Barrientos JC, Kolitz JE, Allen SL, Stamatopoulos K, Rai KR, Sherry B, Chiorazzi N. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia 35(11):3163-3175, 2021. e-Pub 2021. PMID: 33935280.
7. Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia 35(9):2621-2634, 2021. e-Pub 2021. PMID: 33654205.
8. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
9. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
10. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
11. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 35(6):1610-1620, 2021. e-Pub 2020. PMID: 33087831.
12. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
13. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
14. Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, Mongan A. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res 102:106520, 2021. e-Pub 2021. PMID: 33611131.
15. Lazarian G, Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell 39(3):380-393.e8, 2021. PMID: 33689703.
16. Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J 11(3):57, 2021. e-Pub 2021. PMID: 33714981.
17. Mohammad IS, Lin K, Oates M, Khan UT, Burger J, Pettitt AR, Zhuang J. Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia. Leuk Lymphoma 62(1):1-13, 2021. e-Pub 2020. PMID: 32856983.
18. Smith CIE, Burger JA. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Front Immunol 12:689472, 2021. e-Pub 2021. PMID: 34177947.
19. Burger JA. Integrating New Therapies for Chronic Lymphocytic Leukemia. Cancer J 27(4):275-285, 2021. PMID: 34398554.
20. Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop 60(4):130-137, 2020. e-Pub 2020. PMID: 32404571.
21. de Castro CG, Gregianin LJ, Burger JA. Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leuk Lymphoma 61(10):1-2, 2020. e-Pub 2020. PMID: 32611256.
22. Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res 97:106432, 2020. e-Pub 2020. PMID: 32911375.
23. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
24. Liu W, Burger JA, Xu J, Tang Z, Toruner G, Khanlari M, Medeiros LJ, Tang G. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. Ann Hematol 99(10):2343-2349, 2020. e-Pub 2020. PMID: 32833105.
25. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study. Clin Cancer Res 26(15):3918-3927, 2020. e-Pub 2020. PMID: 32209572.
26. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
27. Burger JA. Treatment of Chronic Lymphocytic Leukemia. N Engl J Med 383(5):460-473, 2020. PMID: 32726532.
28. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. e-Pub 2020. PMID: 32681739.
29. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2019. PMID: 31862959.
30. Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica 105(4):e164-e168, 2020. e-Pub 2019. PMID: 31413095.
31. Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34(3):787-798, 2020. e-Pub 2019. PMID: 31628428.
32. Blevins JL, Carroll KM, Burger JA, Pearle AD, Bostrom MP, Haas SB, Sculco TP, Jerabek SA, Mayman DJ. Postoperative outcomes of total knee arthroplasty compared to unicompartmental knee arthroplasty: A matched comparison. Knee 27(2):565-571, 2020. e-Pub 2020. PMID: 32014411.
33. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
34. Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol 11(1):19-23, 2020. e-Pub 2019. PMID: 31005650.
35. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2019. PMID: 31553487.
36. Malek AE, Gutierrez C, Mulanovich VE, Botdorf J, Chemaly RF, Shah S, McCall BM, Melancon JT, McConn KK, Borjan J, Raad II, Burger JA, Garcia-Manero G, Adachi JA. Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts. Mediterr J Hematol Infect Dis 12(1):e2020044, 2020. e-Pub 2020. PMID: 32670522.
37. Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N. Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 60(13):1-2, 2019. e-Pub 2019. PMID: 31305193.
38. Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma 60(14):1-9, 2019. e-Pub 2019. PMID: 31352850.
39. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: up to 6?years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94(12):1353-1363, 2019. e-Pub 2019. PMID: 31512258.
40. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
41. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
42. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med 8(15):6559-6565, 2019. e-Pub 2019. PMID: 31502383.
43. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Undetectable MRD Using Next Generation Sequencing is Associated With Improved PFS After Treatment with FCR for CLL. Blood 134(22):1951-1959, 2019. e-Pub 2019. PMID: 31537528.
44. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Blood 134(21):1811-1820, 2019. e-Pub 2019. PMID: 31558467.
45. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
46. Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J 25(6):386-393, 2019. PMID: 31764119.
47. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
48. Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 134(11):851-859, 2019. e-Pub 2019. PMID: 31340982.
49. Yigit B, Wang N, Ten Hacken E, Chen SS, Bhan AK, Suarez-Fueyo A, Katsuyama E, Tsokos GC, Chiorazzi N, Wu CJ, Burger JA, Herzog RW, Engel P, Terhorst C. SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res 7(9):1485-1496, 2019. e-Pub 2019. PMID: 31315913.
50. Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A. Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. Br J Haematol 186(1):175-180, 2019. e-Pub 2019. PMID: 30739324.
51. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 186(1):184-188, 2019. e-Pub 2019. PMID: 30740654.
52. Boddu P, Gibbons J, Burger J, Sivina M, Thakral B, Kanagal-Shamanna R, Ferrajoli A. Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leuk Lymphoma 60(6):1-4, 2019. e-Pub 2019. PMID: 30632839.
53. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
54. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 3(12):1799-1807, 2019. PMID: 31196847.
55. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 185(3):606-608, 2019. e-Pub 2018. PMID: 30406944.
56. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis. Am J Hematol 94(5):554-562, 2019. e-Pub 2019. PMID: 30767298.
57. Morande PE, Sivina M, Uriepero A, Seija N, Berca C, Fresia P, Landoni AI, Di Noia JM, Burger JA, Oppezzo P. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood 133(19):2056-2068, 2019. e-Pub 2019. PMID: 30814061.
58. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab. Blood 133(19):2031-2042, 2019. e-Pub 2019. PMID: 30842083.
59. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. PMID: 31076409.
60. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
61. Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma 60(4):1-6, 2019. e-Pub 2018. PMID: 30277101.
62. Hamlin PA, Flinn IW, Wagner-Johnston N, Burger JA, Coffey GP, Conley PB, Michelson G, Leeds JM, Der K, Kim Y, Sabalvaro-Torres A, Birrell M, Pandey A, Curnutte JT, Patel MR. Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. Am J Hematol 94(4):E90-E93, 2019. e-Pub 2019. PMID: 30592080.
63. Burger JA. Going through changes: surface IgM levels during CLL therapy with ibrutinib. Clin Cancer Res 25(8):2372-2374, 2019. e-Pub 2019. PMID: 30728153.
64. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2018. PMID: 30530801.
65. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol 184(4):558-569, 2019. e-Pub 2018. PMID: 30506764.
66. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2018. PMID: 30508305.
67. Ten Hacken E, Gounari M, Ghia P, Burger JA. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia 33(2):287-298, 2019. e-Pub 2018. PMID: 30555163.
68. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 6(2):e100-e109, 2019. PMID: 30709431.
69. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
70. Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies. Am J Hematol 93(11):1402-1410, 2018. e-Pub 2018. PMID: 30129285.
71. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
72. O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol 93(11):1318-1326, 2018. e-Pub 2018. PMID: 30094870.
73. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma 59(11):1-6, 2018. e-Pub 2018. PMID: 29465264.
74. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
75. O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 18(10):648-657.e15, 2018. e-Pub 2018. PMID: 30061088.
76. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85, 2018. e-Pub 2018. PMID: 30245189.
77. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 124(20):4044-4055, 2018. e-Pub 2018. PMID: 30307611.
78. Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 18(10):658-663.e2, 2018. e-Pub 2018. PMID: 30001986.
79. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103(9):1502-1510, 2018. e-Pub 2018. PMID: 29880603.
80. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
81. Peled A, Klein S, Beider K, Burger JA, Abraham M. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine 109:11-16, 2018. PMID: 29903571.
82. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol 93(9):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
83. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget 9(72):33710-33718, 2018. e-Pub 2018. PMID: 30263097.
84. Burger JA, O'Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol 15(8):510-527, 2018. PMID: 29777163.
85. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
86. Jain P, Konoplev S, Benjamini O, Romagura J, Burger JA. Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA). Blood Res 53(2):169-172, 2018. e-Pub 2018. PMID: 29963527.
87. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59(6):1312-1322, 2018. e-Pub 2017. PMID: 28972430.
88. Coutre S, Tedeschi A, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps TJ. Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica 103(6):e249-e251, 2018. e-Pub 2017. PMID: 29170253.
89. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
90. O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 131(17):1910-1919, 2018. e-Pub 2018. PMID: 29437592.
91. Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32(4):960-970, 2018. e-Pub 2017. PMID: 28972595.
92. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9(30):21268-21280, 2018. e-Pub 2018. PMID: 29765537.
93. Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer 18(3):148-167, 2018. e-Pub 2018. PMID: 29348577.
94. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180(4):597-600, 2018. e-Pub 2016. PMID: 27766619.
95. Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med 215(2):681-697, 2018. e-Pub 2018. PMID: 29301866.
96. Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood 131(8):877-887, 2018. e-Pub 2017. PMID: 29191916.
97. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
98. Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs 27(1):31-42, 2018. e-Pub 2017. PMID: 29125406.
99. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology 7(4):e1417720, 2018. e-Pub 2018. PMID: 29632735.
100. Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia 32(1):83-91, 2018. e-Pub 2017. PMID: 28592889.
101. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
102. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
103. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2017. PMID: 29164608.
104. Jain P, Burger JA, Khoury JD. CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation. Am J Hematol 92(10):1113-1114, 2017. e-Pub 2017. PMID: 28670739.
105. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 123(12):2268-2273, 2017. e-Pub 2017. PMID: 28171709.
106. Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJ. The dual Syk/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. Clin Cancer Res 23(9):2313-2324, 2017. e-Pub 2016. PMID: 27697994.
107. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL). Clin Cancer Res 23(9):2154-2158, 2017. e-Pub 2016. PMID: 27797975.
108. Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood 129(19):2612-2615, 2017. e-Pub 2017. PMID: 28373262.
109. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
110. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget 8(13):22104-22112, 2017. e-Pub 2016. PMID: 27655665.
111. Coutré SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, Byrd JC, O'Brien S. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Cancer Res 23(5):1149-1155, 2017. e-Pub 2017. PMID: 28073846.
112. Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA. Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood 129(9):1155-1165, 2017. e-Pub 2016. PMID: 28031181.
113. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
114. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol 198(4):1740-1747, 2017. e-Pub 2017. PMID: 28077600.
115. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2016. PMID: 27673440.
116. Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2(2):e89904, 2017. e-Pub 2017. PMID: 28138560.
117. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E479, 2016. e-Pub 2016. PMID: 27468087.
118. Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca R. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget 7(40):65968-65981, 2016. e-Pub 2016. PMID: 27602755.
119. Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 174(5):760-6, 2016. e-Pub 2016. PMID: 27301277.
120. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant. e-Pub 2016. PMID: 27595282.
121. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol 197(6):2522-31, 2016. e-Pub 2016. PMID: 27534555.
122. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer 122(16):2505-11, 2016. e-Pub 2016. PMID: 27182988.
123. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
124. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia 30(6):1246-54, 2016. e-Pub 2016. PMID: 26847027.
125. Vitale C, Burger JA. Chronic lymphocytic leukemia therapy: new targeted therapies on the way. Expert Opin Pharmacother 17(8):1077-89, 2016. e-Pub 2016. PMID: 26988407.
126. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 101(6):e254-8, 2016. e-Pub 2016. PMID: 27013651.
127. Burger JA. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia. Clin Adv Hematol Oncol 14(5 Suppl 8):7-12, 2016. PMID: 27168204.
128. Coutre SE, Burger JA, Pagel JM. Discussion: Managing Risk When Using Idelalisib. Clin Adv Hematol Oncol 14(5 Suppl 8):13, 2016. PMID: 27168205.
129. Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res 22(10):2359-67, 2016. e-Pub 2016. PMID: 26733610.
130. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun 7:11589, 2016. e-Pub 2016. PMID: 27199251.
131. Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, Burger JA, Rai KR, Chiorazzi N. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30(4):833-43, 2016. e-Pub 2015. PMID: 26582643.
132. Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta 1863(3):401-13, 2016. e-Pub 2015. PMID: 26193078.
133. Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia 30(2):325-30, 2016. e-Pub 2015. PMID: 26290497.
134. Okkenhaug K, Burger JA. PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol 393:123-42, 2016. e-Pub 2015. PMID: 26350103.
135. Burger JA. Obinutuzumab: the more the merrier?. Blood 127(1):6-8, 2016. PMID: 26744434.
136. Koehrer S, Burger JA. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clin Adv Hematol Oncol 14(1):55-65, 2016. PMID: 27057669.
137. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158-64, 2015. e-Pub 2015. PMID: 26308885.
138. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
139. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 373(25):2425-37, 2015. e-Pub 2015. PMID: 26639149.
140. Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894-904, 2015. e-Pub 2015. PMID: 26217876.
141. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121(20):3612-21, 2015. e-Pub 2015. PMID: 26193999.
142. Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 170(1):125-8, 2015. e-Pub 2014. PMID: 25522014.
143. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer 121(14):2375-82, 2015. e-Pub 2015. PMID: 25809968.
144. Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SM. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk 15(7):385-91, 2015. e-Pub 2015. PMID: 25817936.
145. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating M. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma 56(6):1-8, 2015. e-Pub 2014. PMID: 25308294.
146. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High FISH percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol 90(6):471-7, 2015. e-Pub 2015. PMID: 25683856.
147. Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res 21(12):2704-14, 2015. e-Pub 2015. PMID: 25724525.
148. Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 125(19):2915-22, 2015. e-Pub 2015. PMID: 25755291.
149. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res 13(5):944-53, 2015. e-Pub 2015. PMID: 25733697.
150. Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 125(21):3236-45, 2015. e-Pub 2015. PMID: 25795921.
151. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood 125(13):2062-7, 2015. e-Pub 2015. PMID: 25573991.
152. Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell 27(3):409-25, 2015. PMID: 25759025.
153. ten Hacken E, Burger JA. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther 144(3):338-48, 2014. e-Pub 2014. PMID: 25050922.
154. Badar T, Burger JA, Wierda WG, O'Brien S. Ibrutinib: a paradigm shift in management of CLL. Expert Rev Hematol 7(6):705-17, 2014. PMID: 25387837.
155. Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi V. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia 16(12):1036-46, 2014. PMID: 25499217.
156. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer 120(22):3494-501, 2014. e-Pub 2014. PMID: 25043749.
157. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090-9, 2014. e-Pub 2014. PMID: 25150798.
158. Komarova NL, Burger JA, Wodarz D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A 111(38):13906-11, 2014. e-Pub 2014. PMID: 25201956.
159. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis. Mol Cancer Res 12(9):1267-82, 2014. e-Pub 2014. PMID: 24836891.
160. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
161. Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol 166(2):177-88, 2014. e-Pub 2014. PMID: 24697238.
162. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease with first-line chemoimmunotherapy may prompt early treatment discontinuation in chronic lymphocytic leukemia. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
163. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 2014. e-Pub 2014. PMID: 24778152.
164. Ponader S, Burger JA. Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies. J Clin Oncol 32(17):1830-9, 2014. e-Pub 2014. PMID: 24778403.
165. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of chronic lymphocytic leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123(26):4132-5, 2014. e-Pub 2014. PMID: 24829205.
166. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis. Clin Lymphoma Myeloma Leuk 14(3):223-30, 2014. e-Pub 2013. PMID: 24355079.
167. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 14(3):231-8, 2014. e-Pub 2013. PMID: 24440659.
168. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4):973-5, 2014. e-Pub 2013. PMID: 24157581.
169. Burger JA, Okkenhaug K. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies. Nat Rev Clin Oncol 11(4):184-6, 2014. e-Pub 2014. PMID: 24642682.
170. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia. Clin Cancer Res 20(8):2226-35, 2014. e-Pub 2014. PMID: 24583795.
171. Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep 9(1):44-9, 2014. PMID: 24357428.
172. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89(3):282-7, 2014. PMID: 24779033.
173. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 32(9):897-904, 2014. e-Pub 2014. PMID: 24516016.
174. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. Semin Cancer Biol 24:71-81, 2014. e-Pub 2013. PMID: 24018164.
175. Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA. The Spiegelmer(R) NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemo-sensitization. Blood 123(7):1032-9, 2014. e-Pub 2013. PMID: 24277076.
176. ten Hacken E, Burger JA. Molecular Pathways: Targeting the microenvironment in chronic lymphocytic leukemia- focus on the B cell receptor. Clin Cancer Res 20(3):548-56, 2014. e-Pub 2013. PMID: 24323900.
177. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15(1):48-58, 2014. e-Pub 2013. PMID: 24332241.
178. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88(12):1024-9, 2013. e-Pub 2013. PMID: 23913852.
179. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34(12):592-601, 2013. e-Pub 2013. PMID: 23928062.
180. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clin Lymphoma Myeloma Leuk 13(6):693-9, 2013. e-Pub 2013. PMID: 24060289.
181. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 2013. e-Pub 2013. PMID: 23943357.
182. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54(11):2385-2391, 2013. e-Pub 2013. PMID: 23425038.
183. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214-21, 2013. e-Pub 2013. PMID: 23836561.
184. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32-42, 2013. e-Pub 2013. PMID: 23782158.
185. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer 12:50, 2013. e-Pub 2013. PMID: 23725032.
186. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-62, 2013. e-Pub 2013. PMID: 23613521.
187. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 31(5):584-91, 2013. e-Pub 2012. PMID: 23270003.
188. Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 121(9):1501-9, 2013. e-Pub 2012. PMID: 23264597.
189. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One 8(12):e83830, 2013. e-Pub 2013. PMID: 24376763.
190. Burger JA. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 24(6):643-9, 2012. e-Pub 2012. PMID: 22960555.
191. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 2012. e-Pub 2012. PMID: 22282348.
192. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia 26(8):1812-20, 2012. e-Pub 2012. PMID: 22460735.
193. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 2012. e-Pub 2012. PMID: 22534616.
194. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26(7):1576-83, 2012. e-Pub 2012. PMID: 22362000.
195. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 2012. e-Pub 2012. PMID: 22422826.
196. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Th17 and non-Th17 IL-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 97(4):599-607, 2012. e-Pub 2011. PMID: 22058222.
197. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13(71):287-97, 2012. PMID: 22541616.
198. Burger JA. Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep 7(1):26-33, 2012. e-Pub 2011. PMID: 22105489.
199. Peled A, Wald O, Burger JA. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21(3):341-53, 2012. e-Pub 2012. PMID: 22283809.
200. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-9, 2012. e-Pub 2011. PMID: 22180443.
201. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 14(3):276-86, 2012. e-Pub 2012. PMID: 22344033.
202. Davids MS, Burger JA. Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol 3(S1), 2012. e-Pub 2012. PMID: 22844583.
203. Burger JA. The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. Expert Opin Med Diagn 6(1):49-57, 2012. e-Pub 2011. PMID: 23480620.
204. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 42(12):1989-2000, 2011. e-Pub 2011. PMID: 21733558.
205. Burger JA, Ford RJ. The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and, emerging targeted therapies. Semin Cancer Biol 21(5):308-12, 2011. e-Pub 2011. PMID: 21945516.
206. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 29(31):4088-95, 2011. e-Pub 2011. PMID: 21969505.
207. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer 117(20):4689-95, 2011. e-Pub 2011. PMID: 21456010.
208. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-23, 2011. e-Pub 2011. PMID: 21821712.
209. Burger JA, Hoellenriegel J. Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia. Oncotarget 2(10):737-8, 2011. e-Pub 2011. PMID: 22006556.
210. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489-98, 2011. e-Pub 2011. PMID: 21725050.
211. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603-12, 2011. e-Pub 2011. PMID: 21803855.
212. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 2011. e-Pub 2011. PMID: 21670470.
213. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-8, 2011. e-Pub 2011. PMID: 21750315.
214. Burger JA, Sivina M, Ravandi F. The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma 52 Suppl 2:94-8, 2011. e-Pub 2011. PMID: 21438839.
215. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 71(11):3831-40, 2011. e-Pub 2011. PMID: 21512135.
216. Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 11(4):621-30, 2011. PMID: 21504328.
217. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-24, 2011. e-Pub 2011. PMID: 21245487.
218. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood 117(5):1662-9, 2011. e-Pub 2010. PMID: 21115978.
219. Burger JA. Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia. Hematology Am Soc Hematol Educ Program 2011:96-103, 2011. PMID: 22160019.
220. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The Great Imitator: Systemic Nocardiosis Mimicking Richter's Transformation in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 28(35):e732-4, 2010. e-Pub 2010. PMID: 20823404.
221. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting. Semin Cancer Biol 20(6):424-30, 2010. e-Pub 2010. PMID: 20883788.
222. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-2077, 2010. e-Pub 2010. PMID: 20466853.
223. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced response in CLL primary cells. Blood 116(7):1083-91, 2010. e-Pub 2010. PMID: 20442367.
224. Quiroga MP, Burger JA. BCR-Mediated Decrease of CXCR4 and CD62L in CLL - Letter. Cancer Res 70(12):5194; author reply 5195, 2010. e-Pub 2010. PMID: 20501831.
225. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia 24(3):666-8, 2010. e-Pub 2010. PMID: 20054352.
226. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2010. e-Pub 2009. PMID: 19895616.
227. Gandhi V, Burger JA. Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res 15(24):7456-7461, 2009. e-Pub 2009. PMID: 19996200.
228. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis. Blood 114(20):4441-50, 2009. e-Pub 2009. PMID: 19762485.
229. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114(16):3367-75, 2009. e-Pub 2009. PMID: 19636060.
230. Burger JA, Gandhi V. The lymphatic tissue microenvironments in Chronic Lymphocytic Leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood 114(12):2560-1, 2009. PMID: 19762501.
231. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 2009. e-Pub 2009. PMID: 19567878.
232. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 2009. e-Pub 2009. PMID: 19517462.
233. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406. Blood 114(5):1029-37, 2009. e-Pub 2009. PMID: 19491390.
234. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113(19):4604-13, 2009. e-Pub 2009. PMID: 19228923.
235. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113(22):5549-57, 2009. e-Pub 2009. PMID: 19318683.
236. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics Associated With Important Clinical End Points in Patients with Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 2009. e-Pub 2009. PMID: 19224852.
237. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs 18(4):481-90, 2009. PMID: 19335276.
238. Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-Level Expression of the T Cell Chemokines CCl3 and CCL4 by Chronic Lymphocytic Leukemia B cells in nurselike cell co-cultures and after BCR stimulation. Blood 113(13):3050-8, 2009. e-Pub 2008. PMID: 19074730.
239. Burger JA, Bürkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 137(4):288-96, 2007. PMID: 17456052.
240. Zeiser R, Mikesch K, Fisch P, Schaefer HE, Burger JA. Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol 125(6):679, 2004. PMID: 15180856.
241. Horner AA, Widhopf GF, Burger JA, Takabayashi K, Cinman N, Ronaghy A, Spiegelberg HL, Raz E. Immunostimulatory DNA inhibits IL-4 dependent lgE synthesis by human B cells. J Allergy Clin Immunol 108(3):417-423, 2001. PMID: 11544462.
242. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 107(3):305-15, 2001. PMID: 11160154.
243. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (Cover Illustration) 96(8):2655-63, 2000. PMID: 11023495.
244. Burger J, Ochs A, Wirth K, Berger DP, Mertelsmann R, Engelhardt R, Roessle M, Haag K. The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol 8(2):200-202, 1997. PMID: 9093733.

Editorials

1. Burger JA. CLL cells are moved by the MARCKS brothers. Blood 138(7):503-504, 2021. PMID: 34410355.
2. Burger JA. New pieces in the BTKi resistance puzzle. Blood 131(18):1995-1996, 2018. PMID: 29724714.
3. Ten Hacken E, Burger JA. HSP90, a chaperone that can make you SYK. Blood 129(5):542-544, 2017. PMID: 28153836.
4. Burger JA. Osteopontin: an unhealthy sleep remedy for ALL. Blood 121(24):4814-5, 2013. PMID: 23766457.
5. Burger JA. BRAF mutation: supporting diversity in HCL. Blood 119(14):3193-4, 2012. PMID: 22493212.
6. Burger JA. Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. Leuk Lymphoma 53(1):3-4, 2012. PMID: 21830996.
7. Burger JA. Angiopoietin-2 in CLL. Blood 116(4):508-09, 2010. PMID: 20671131.
8. Burger JA and Gandhi V. Tissue microenvironments and drug resistance in Chronic Lymphocytic Leukemia: ABT-737 must overcome the same hurdles as our older drugs. Faculty 1000 Medicine, 2009.
9. Burger JA. CXCR4 in acute myelogenous leukemia (AML): When too much attraction is bad for you. Leuk Res 18(4):747-48, 2009. PMID: 19091405.
10. Burger, JA . Fledgling prognostic markers in CLL. Blood 110(12):3820-21, 2007.
11. Burger JA. No cell is an island unto itself: The stromal microenvironment in chronic lymphocytic leukemia. Leuk Res 31(7):887-8, 2007. PMID: 17234265.

Abstracts

1. Sasaki K, Jabbour E, Naqvi K, Skinner J, Anderson K, Dellasala SE, Yilmaz M, Ferrajoli A., Bose P, Thompson PA, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Burger JA, Borthakur G, Pemmaraju N, Khouri R, Paul S, Pierce SA, Cortes JE, Kantarjian HM. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
2. Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens D, Dai S, Cheung L, Kwei K, Lal I, Hsu E, Kipps T, Tedeschi A. Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
3. Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriael P, Jain N, Debaja BS, Masarova L, Kadia TM, Paul S, Nichols D, Garcia-Manero G, Burger JA, diNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Bose P, Khouri R, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour E. CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
4. Sivina M, Jain N, Kim E, Kadia TM, Estrov ZE, Ohanian M, Andreeff M, Thomas M, Thompson PA, Kantarjian HM, Keating MJ, O'Brien SM, Wierda WG, Ferrajoli A, Burger JA,. Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
5. Maiti A, Jabbour E, Jain N, Borthakur G, Kadia TM, Burger JA, Wierda WG, Konopleva M, Alvarado Y, Short NJ, Faderl S, O'Brien SM, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Khoury JD, Balkin H, Kelly M, Azzawi H, Garris R, Garcia-Manero G, Kantarjian HM, Ravandi F. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
6. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Kadia TM, Khoury JD, Jorgensen JL, Wang SA, Alvarado Y, Burger JA, Daver N, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda WG, Kornblau SM, Jacob J, Rostykus M, Kwari M, Rausch CR, Loiselle C, Milton A, Rivera J, Garris R, O'Brien SM, Jabbour E. Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
7. Maiti A, DiNardo CD, Wang SA, Jorgensen JL, Kadia TM, Daver N, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour E, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalben-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano K, Pierce S, Kantarjian HM, Konopleva M, Ravandi F. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
8. Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Jain N, Dabaja BS, Alvarado Y, Kadia TM, Paul S, Chew S, Garcia-Manero G, Burger JA, diNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Ohanian M, Khouri M, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour E. Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
9. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Sasaki K, Fowler NH, Kadia TM, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL, Wang SA, Garg N, Wang X, Wei CJ, Crus N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
10. Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Barbara-Mourelle A, Dunford An, anand S, Delgado J, Hess JM, Taylor-Weiner A, Kretzner H, Munoz PB, Shaughnessy CJ, Fernandes SM, Sivina M, Rassenti LZ, Meissner A, Wiestner A, Burger JA, Kipps TJ, Brown JR, Hallek M, Aguet F, Neuberg DS, Puente XS, Steward C, Martin-Subero JI, Stigenbauer S, Wu CJ, Campo E, Getz G. The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
11. Cherng HJJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson PA, Burger JA, Ferrajoli A, Estrov ZE, O'Brien SM, Keating MJ, Wierda WG, Jain N. Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
12. Saxena K, Konopleva M, Bhagat TD, Guerra VA, Maduike R, Tizani S, Borthakur G, Jabbour E, Pemmaraju N, Kadia TM, Short NJ, Burger JA, Kornblau SM, Daver N, Naqvi K, Cai T, Kuruvilla VM, Kantarjian HM, Garcia-Manero G, Verma A, DiNardo CD. AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
13. Short NJ, Kadia TM, diNardo CD, Pemmaraju N, Borthakur G, Garcia-Manero G, Jabbour E, Sasaki K, Issa GC, Montalban-Bravo G, Bose P, Burger JA, Miller D, Alexander-Williams L, Ravandi F, Konopleva M, Kanarjian HM, Daver N. Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
14. Jones J, George B S, Peterson C, Tran TM, Burger JA, Jain N, Keating MJ, Wierda WG, Durand JB, Ferrajoli A. Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib. Blood (ASH Annual Meeting Abstract) 136(1 (Supp)), 2020.
15. Short NJ, Kantarjian H, Ravandi F, Huang X,, Jain N, Sasaki K, Khouri R, Daver NG, Pemmaraju N, Khoury JD, Jorgensent JL, Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia TM, Yilmaz ME, Borthakur GM, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Jacob J, Rostykus M, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, O'Brien SM, Jabbour E. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
16. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
17. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
18. Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Verstovsek S, Wierda WG, Keting MJ, Estrov ZE. Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
19. Jain N, Keating M, Thompson PA, Burger JA, Ferrajoli A, Estrov ZE, Borthakur GM, Takahashi K, Bose P, Fowler NH, Kadia TM, Daver NG, Konopleva MY, Alvarado Y, Yilmaz M, diNardo CD, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang S, Garg N, Wang X, Sondermann K, Cruz N, Wei CJ, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
20. Guerra VA, Burger JA, Borthakur GM, Jabbour E, Pemmaraju N, Kadia TM, Garcia-Manero G, Kantarjian HM, Konopleva MY, DiNardo CD. Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
21. Saba NS, Meyers J, Fontan L, Melnick A, Wiestner A, Lobelle-Rich P, Kim E, Burger JA, Mouawas Y, Deininger PL, socola F, Safah H, Flemington EK. The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
22. Kim E, Zhang H, Sivina M, Vaca A, Thompson PA, Jain N, Ferrajoli A, Estrov ZE, Keating MJ, Wierda WG, Rice WG, Andreeff M, Burger JA. CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
23. Jain N, Thompson PA, Burger JA, Ferrajoli A, Takahashi K, Estrov ZE, Borthakur GM, Bose P, Kadia TM, Pemmaraju N, Sasaki K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien S, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
24. Cull G, Simpson D, Opat S, Burger JA, Trotman J, Marlton P, Gottlieb D, Munoz J, Seymour JF, Roberts AW, Wu K, Atwal S, Novotny W, Huang J, Tam CS. Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
25. Vaca A, Sivina M, Clise-Dwyer K, Kim E, Keating MJ, Ferrajoli A, Wierda WG, Li D, Ma Q, Burger JA. Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019.
26. Tedeschi Alessandra, Greil Richard, Demirkan Fatih, Robak Tadeusz, Moreno Carol, Barr Paul, Anz Bertrand, Simpson David, Gaidano Gianluca, Bairey Osnat, Stevens Don, Gill Devinder, Flinn Ian W., Kipps Thomas J., Burger Jan A., Lin Jennifer, Webb Thomas, Fedorov Viktor, Styles Lori, Gribben John G.. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
27. Strati P, Sivina M, Kim Ekaterina, Keating M, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Burger JA. Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
28. Short NJ, Jabbour EJ, Ravandi F, Huang X, Jain N, Sasaki K, Pemmaraju N, Daver NG, Khoury JD, Jorgensen JL, Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Nasnas P, Jacob J, Garris RE, O'Brien SM, Kantarjian HM. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
29. Byrd JC, Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA, Sharman J, Wierda WG, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien SM. Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
30. Thompson PA, Srivastava J, Strati P, Jorgensen JL, Breaker J, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov ZE, Jain N, Wierda WG. Undetectable-Minimal Residual Disease (U-MRD6) (10-6 sensitivity) Is Associated with Best Progression-Free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10-4 sensitivity) with First-Line FCR . Blood (ASH Annual Meeting Abstracts) 132(1 (Supp)), 2018.
31. Aboudalle I, Kantarjian HM, Ohanian MN, Alvarado Y, Jabbour EJ, Garcia-Manero G, Naqvi K, Wierda WG, Daver NG, Burger JA, Konopleva MY, Takahashi K, Andreeff M, Pemmaraju N, Ferrajoli A, Borthakur G, Kadia TM, Ravandi F, Cortes JE. Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
32. Bose P, McCue D, Wiederhold NP, Kadia TM, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson PA, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
33. Strati P, Takahashi K, Keating MJ, Thompson PA, Hinojosa C, Rodriguez D, Daver NG, Jain N, Burger JA, Estrov ZE, O'Brien SM, Kantarjian HM, Wierda WG, Futreal A, Ferrajoli A. Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
34. Jain N, Ferrajoli A, Basu S, Thompson PA, Burger JA, Kadia TM, Estrov ZE, Pemmaraju N, Lopez W, Thakral B, Khoury JD, Bueso-Ramos CE, Blando J, O'Brien SM, Kantarjian HM, Allison JP, Keating MJ, Sharma P, Wierda WG. A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation . Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
35. Rozovski U, Li P, Harris DM, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov ZE. Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
36. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
37. Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr P, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. Blood (Ash Annual Meeting Abstracts) 132(1 (Supp)), 2018.
38. Burger JA, Sivina M, Ferrajoli A, Jain N, Kim Ekaterina, Kadia T, Estrov Z, Gonzalez GN, Huang X, Ohanian M, Andreeff M, Thomas M, Alexander-Williams L, Kantarjian HM, O'Brien SM, Wierda WG, Keating MJ. Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
39. Tedeschi A, Owen CJ, Robak T, Barr PM, Bairey O, Hillmen P, coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Siddiqi T, Iyer G, Lal ID, Trudeau J, Dai S, Dean JP, James DF, Burger JA, Ghia P, Kipps TJ. Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
40. Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
41. Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Takahashi K, Garg N, Wang X, Gandhi V, Plunkett W, Kanagal-Shamanna R, Patel K, Lopez W, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
42. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Daver N, Thomas DA, Pemmaraju N, Khouri R, Khoury JD, Jorgensen JL, Alvarado Y, Sasaki K, Konopleva M, Garcia-Manero G, Kadia T, Cortes JE, Benton CB, Borthakur G, Burger JA, Ohanian M, Wierda WG, Estrov Z, Kornblau S, DiNardo CD, Ferrajoli A, Jacob J, Manzoor A, Garris R, O'Brien SM, Jabbour EJ. A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
43. Rozovski U, Harris DM, Li P, Manshouri T, Veletic I, Bueso-Ramos C, Jain P, Verstovsek S, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
44. Hu B, Patel K, Wang X, Chen HC, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok Y, Loghavi S, Wierda WG. Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
45. Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ, Wierda WG. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
46. Kim E, Hacken ET, Clarke A, Keating MJ, Wierda WG, Ferrajoli A, Jain N, Thompson PA, Estrov Z, Burger JA. The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
47. Chen SS, Ravichandran P, Ferrer G, Mazzarello AN, Palacios F, Ibrahim M, Kieso Y, Barrientos JC, Clark E, Sherry B, Burger JA, Rai K, Chiorazzi. Ibrutinib Disrupts IL-4R - IL-4 Axis By Inhibiting IL-4R Signaling and Reversing Th2/Th1 Polarization through Diminished CLECL1 in CLL B Cells. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
48. Chamoun K, Kantarjian HM, Akosile A, Assi R, Ravandi F, Borthakur G, Garcia-Manero G, Kadia T, Konopleva M, Estrov Z, DiNardo CD, Daver N, Pemmaraju N, Ferrojoli A, Burger JA, Wierda WG, Jabbour EJ, Cortes JE. Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
49. Hacken ET, Valentin R, Sun J, Deng J, Brooks An, Werner L, Regis FF, Gruber M, Wond J, Cartun Z, Seiler M, Smith P, Thomas M, Buonamici S, Ghia E, Kim e, Rassenti LZ, Burger JA, Kipps TJ, Meyerson M, Neuberg DS, Carrasco RD, Wang L, Davids MS, Letai a, Wu CJ. Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
50. Assi R, Kantarjian HM, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo CD, Khouri M, Burger JA, Cortes JE, Jain N, Wierda WG, Chamoun S, Konopleva M, Jabbour EJ. Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
51. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
52. Sivina M, Kim E, Pacelli C, Keating MJ, Ferrajoli A, Wierda WG, Burger JA. CXCL13 (BCA-1) Plasma Levels Are a Useful Biological Marker for Disease Progression in Chronic Lymphocytic Leukemia (CLL) Patients. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
53. Jain P, Burger JA, Gonzalez GN, Kanagal-Shamanna R, Rozovski U, Tam CS, Wierda WG, Thompson PA, Sarwari N, Luthra R, Quesada A, Jain N, Ferrajoli A, Kantarjian HM, Cortes JE, O'Brien SM, Keating MJ, Estrov Z. Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
54. Aboudalle I, Kantarjian HM, Burger JA, Estrov Z, Ohanian M, Jabbour EJ, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Cortes JE. Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
55. Shah AR, Muzzafar T, Asad R, Peterson CB, Kantarjian HM, Ferrajoli A, Wierda WG, Burger JA, Jain N, Borthakur G, Khan M, Chilkulwar A, Randolph B, Gowda L, Keating MJ. Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR). Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
56. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, \bBurger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells. Blood (Ash Annual Meeting Abstracts) 130(1 (Supp)), 2017.
57. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pmmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Thakral B, Bueso-Ramos C, Blando J, O'Brien S, Kantarjian H, Allison J, Keating M, Sharma P, Wierda W,. Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial. Blood (ASH Annual Meeting Abstracts), 2016.
58. Abaza Y, Kantarjian H, Jabbour E, Thomas DA, Kadia T, Borthakur G, Burger JA, Wierda W, Jain N, Faderl S, O'Brien S, Konopleva M, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Bose, Thompson PA, Kelly M, Garris R, Garcia-Manero G, Cortes JE, Ravandi F. Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood (ASH Annual Meeting Abstracts), 2016.
59. Landau DA, Sun C, Daniel Rosebrock D, Campbell M, Herman SE, Hoellenriegel J, Farooqui M, Zhang W, Neuberg D, Livitz D, Leshchiner I, Getz G, Burger JA, Wiestner A, Wu CJ. The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL. Blood (ASH Annual Meeting Abstracts), 2016.
60. Thompson PA, Strati P, Keating M, O'Brien S, Ferrajoli A, Burger JA, Jorgensen JL, Faderl S, Estrov Z, Jain N, Kadia T, Borthakur G, DiNardo C, Daver N, Jabbour E, Wierda W. Early Achievement of MRD-Negativity in IGHV-Mutated (IGHV-M) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse. Blood (ASH Annual Meeting Abstracts), 2016.
61. O'Brien S, Furman R, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd J. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Clinically Relevant Abstract. Blood (ASH Annual Meeting Abstracts), 2016.
62. Barr P, Robak T, Owen CJ, Tedeschi A, Bairey O, Bartlett N, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James DF, Kipps T, Ghia P. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood (ASH Annual Meeting), 2016.
63. Havranek O, Xu J, Koehrer S, Wang Z, Comer J, Becker L, Yi AF, Burger JA, Westin J, Zal T, Davis RE. Molecular Aspects of Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma Provide Biomarkers and Targets for Specific Inhibition. Blood (ASH Annual Meeting Abstracts), 2016.
64. Sasaki K, Jabbour E, O'Brien S, Ravandi F, Thomas DA, Kadia T, Garcia-Manero G, Burger JA, Pemmaraju N, Alvarado Y, Daver N, Jain N, Konopleva M, Champlin RE, Khouri IF, Kebriaei P, Marin D, DiNardo C, Estrov Z, Takahashi K, Short NJ, Khouri MR, Jacob J, Garris R, Cortes JE, Kantarjian H. Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 2016.
65. Ohanian M Garcia-Manero G, Jabbour E, Daver N, Borthakur G, Kadia T, Brandt M, Pierce S, Burger JA, Richie MA, Patel K, Cortes JE, Kantarjian H, Ravandi F. Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITD mutation. Blood (ASH Annual Meeting Abstracts), 2016.
66. Sam PY, Ahaneku H, Nogueras-Gonzalez G, Jabbour E, Garcia-Manero G, Borthakur G, Wierda W, Daver N, Kadia T, Burger JA, Pierce S, DiNardo C, Ravandi F, Kantarjian H, Cortes JE. Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood (ASH Annual Meeting Abstracts), 2016.
67. Jain N, Basu S, Thakral B, Burger JA, Thompson PA, Ferrajoli A, Estrov Z, Bueso-Ramos C, Stingo F, Bassett R, Daver N, Kadia T, Matthews J, Flores W, Somani N, Blando J, Kantarjian H, Allison J, Keating M, Sharma P, Wierda W. Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts), 2016.
68. Woyach J, Hillmen P, Brown JR, Coutre S, Barr P, O'Brien S, Barrientos J, Devereux S, Kay N, Reddy N, Mulligan S, Tedeschi A, Zhou C, Ninomoto J, James DF, Byrd J, Burger JA. Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). Blood (ASH Annual Meeting Abstracts), 2016.
69. Chihara D, Thompson PA, Kantarjian H, O'Brien S, Ferrajoli A, Jain N, Burger JA, Estrov Z, Faderl S, Wierda W, Keating M. Chemoimmunotherapy for Patients with Chronic Lymphocytic Leukemia: MD Anderson Experience Beyond FCR300. Blood (ASH Annual Meeting Abstracts), 2016.
70. Ohanian M, Kantarjian H, Borthakur G, Kadia T, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour E, Daver N, Kornblau S, Wierda W, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt J, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood (ASH Annual Meeting Abstracts), 2016.
71. Sasaki K, Kantarjian H, Ravandi F, Daver N, Kadia T, Khouri R, Alvarado Y, Burger JA, Thomas DA, Garcia-Manero G, DiNardo C, Pemmaraju N, Short NJ, Schroeder H, Garris R, Bose P, Jain N, Naqvi K, Wierda W, Verstovsek S, Cortes JE, Konopleva M, O'Brien S, Jabbour E. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood (ASH Annual Meeting Abstracts), 2016.
72. Boddu P, Kantarjian H, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger JA, Kornblau S, Dellasala S, Pierce S, Jabbour E, Cortes JE. Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. Blood (ASH Annual Meeting Abstracts), 2016.
73. Coutre S, Byrd J, Hillmen P, Barrientos J, Barr P, Devereux S, Robak T, Kipps T, Schuh, MD PhD A, Moreno C, Furman R, Burger JA, O'Dwyer M, Ghia P, Valentino R, Suzuki S, Ninomoto J, James DF, O'Brien S. Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood (ASH Annual Meeting Abstracts), 2016.
74. Rozovski U, Harris DH, LI P, Liu P, Jain P, Ferrajoli A, Burger JA, O'Brien S, Bose P, Thompson PA, Jain N, Wierda W, Keating M, Estrov Z. Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo. Blood (ASH Annual Meeting Abstracts), 2016.
75. Tambaro FP, Criscuolo C, Jain N, Ferrajoli A, Thompson PA, Burger JA, Estrov Z, Ripaldi M, Kantarjian H, O'Brien S, Keating M, Wierda W. CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment. Blood (ASH Annual Meeting Abstracts) 128(22), 2016.
76. Rozovski U, Harris DM, LI P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien S, Bose P, Thompson PA, Jain N, Wierda W, Keating M, Estrov Z. Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells. Blood (ASH Annual Meeting Abstracts) 128(22), 2016.
77. Strati P, Thompson PA, Keating M, Hinojosa C, Rodriguez D, Wang X, Daver N, Jain N, Burger JA, Estrov Z, Wierda W, Kantarjian H, Obrien S, Ferrajoli A. A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 128(22), 2016.
78. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda W. Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib. Blood (ASH Annual Meeting Abstracts) 128(22), 2016.
79. Schliffke S, Sivina M, Kim E, Thiele B, Akyüz N, Falker-Gieske C, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M. Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 128(22), 2016.
80. Ian Flinn, Paul A. Hamlin, Donald K Strickland, Anjali Pandey, Matt Birrell, Greg Coffey, Janet Leeds, John T Curnutte, Jan Andreas Burger, Nina D. Wagner-Johnston, Manish R. Patel; Sarah Cannon. Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity. JCO (ASCO Annual Meeting Abstracts), 2015.
81. Loretta A. Williams, Araceli Garcia-Gonzalez, Hycienth Ahaneku, Jorge E. Cortes, Guillermo Garcia-Manero, Hagop M. Kantarjian, Qiuling Shi, Gautam Borthakur, Jan Andreas Burger, Elias Jabbour, Koichi Takahashi, Huei-Kai Lin, Achala Limaye, Charles S. Cleeland. A patient-reported outcome measure for symptoms of AML/MDS. JCO (ASCO Annual Meeting Abstracts), 2015.
82. Paul A. Hamlin, Ian Flinn, Nina Wagner-Johnston, Jan Burger, Glenn Michelson, Anjali Pandey, Matt Birrell, Greg Coffey, Janet Leeds, Alice sabalvaro-Torres, Yvonne Kim, John T Curnutte, Manish R. Patel. Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies—Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing. JCO (ASCO Annual Meeting Abstracts), 2015.
83. Burger J. The microenvironment in CLL: cellular and molecular players and emerging therapeutic targets. AACR Special Conference on Hematologic Malignancies: Translating Discovery to Novel Therapy, 2014.
84. Randhawa S, Ghosh D, Peled A, Davis RE, Burger J. Targeting the CXCR4 Chemokine Receptor Thwarts Stromal Cell Mediated Drug Resistance in B-Cell Acute Lymphoblastic Leukemia (B-ALL). AACR 2014 Annual Meeting, 2014.
85. Burger J. Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition. Blood (ASH Annual Meeting Abstracts), 2013.
86. Rosin N, Kim E, Koehrer S, Wang Z, O’Brien S, Wierda W, Thomas D, Estrov Z, Kantarjian H, Lannutti B, Quéva C, DavisR, Burger J. Gene Expression Profiling and Western Blot Analyses Demonstrated Down Regulation of Pre-B Cell Receptor Signaling after GS-1101 Treatment in Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 2013.
87. ten Hacken E, Scielzo C, Wierda W, Keating M, O’Brien S, Ghia P, Caligaris-Cappio F, Burger J. Ibrutinib differentially interferes with surface IgM and IgD BCR signaling kinetics in Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts), 2013.
88. Hoellenriegel J, Hartmann E, Rosenwald A, O’Brien S, Keating M, Wierda W, Buggy J, Burger J. Longitudinal Gene Expression Profiling Reveals Down-regulation of BCR Signaling-related Genes in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib plus Rituximab. Blood (ASH Annual Meeting Abstracts), 2013.
89. Köhrer S, Davis R, Coffey G, Kim E, Rosin N, ten Hacken E, O’BrienS, Wierda W, Estrov Z, Thomas D, Kantarjian H, Wang Z, Jumaa H, Burger J. Pre-BCR Signaling Activity Predicts Sensitivity to Syk Kinase Inhibition In B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood (ASH Annual Meeting Abstracts), 2013.
90. Kim E, Koehrer S, Rosin N, Wang Z, Thomas D, Ravandi R, Kornblau S, Kantarjian H, O'Brien S, Estrov Z, Buggy J, Muschen M, Davis R, Burger J. Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts), 2013.
91. Andreeff M, Zeng Z, Kelly MA, Wang R, McQueen T, Duvvuri S, Nowshad G, Borthakur G, Burger JA, Kadia TM, Jabbour E, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib : Results From a Phase I Trial in Relapsed/Refractory AML Patients. Blood (ASH Annual Meeting Abstracts), 2012.
92. Falchi L, Kantarjian HM, Quintas-Cardama A, O'Brien S, Jabbour EJ, Ravandi F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 132(1 (Supp)), 2012.
93. Hoellenriegel J, O'Brien S, Keating MJ, Wierda WG, Buggy JJ, Burger JA. In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton’s Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial. Blood (ASH Annual Meeting Abstracts), 2012.
94. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Ferrajoli A, Faderl S, Lerner S, Zacharian G, Huang X, James DF, Buggy JJ, Kantarjian HM, O'Brien SM. The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients. Blood (ASH Annual Meeting Abstracts), 2012.
95. Byrd JC, Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA, Sharman JP, Grant B, Jones JA, Wierda WG, Zhao W, Heerema NA, Johnson AJ, Tran A, Clow F, Kunkel L, James DF, O'Brien S. The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. Blood (ASH Annual Meeting Abstracts), 2012.
96. Zboralski D, Hoellenriegel J, Maasch C, Kruschinski A, Burger JA. Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization. Blood (ASH Annual Meeting Abstracts), 2012.
97. Wierda WG, Balakrishnan K, Ferrajoli A, O'Brien S, Burger JA, Kadia TM, Cortes JE, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi VV. Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy. Blood (ASH Annual Meeting Abstracts), 2012.
98. Jain P, Kantarjian HM, Thomas DA, Ravandi F, Kadia TM, Burger JA, Borthakur G, Cortes JE, Daver N, Jabbour EJ, Koller CA, Konopleva M, Pemmaraju N, Kelly MA, Garris R, O'Brien S, Faderl S. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts), 2012.
99. Ravandi F, Alattar ML, Levis MJ, Garcia-Manero G, Richie MA, Daver NG, Faderl S, Andreeff M, Borthakur G, Burger JA, Kadia TM, Grunwald MR, Dellasala SE, Cortes JE, Kantarjian HM. Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood (ASH Annual Meeting Abstracts) 132(1 (Supp)), 2012.
100. Yilmaz M, Kantarjian HM, Jabbour EJ, O'Brien SM, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger JA, Pierce SA, Quintás-Cardama A, Cortes JE. The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution. Blood (ASH Annual Meeting Abstracts), 2012.
101. Sivina M, Kreitman RJ, Arons E, Buggy JJ, Ravandi F, Burger JA. Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL. Blood (ASH Annual Meeting Abstracts) 132(1 (Supp)), 2012.
102. Kim E, Koehrer S, Rosin NY, Thomas DA, Ravandi F, Kornblau SM, Kantarjian HM, O'Brien S, Estrov Z, Buggy JJ, Burger JA. Activity of Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood (ASH Annual Meeting Abstracts) 132(1 (Supp)), 2012.
103. Takahashi K, Sivina M, Oki Y, Fayad LE, Neelapu SS, Kwak LW, Xiao L, Huang X, Fu K, Chan WC, Vose JM, Kantarjian HM, Keating M, Burger JA. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. Blood (ASH Annual Meeting Abstracts), 2012.
104. Rozovski U, Calin G, Tetsirp S, D'Abundo L, Harris D, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien SM, Wierda WG, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA Genes in Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts), 2012.
105. Jain P, Trinh LX, Benjamini O, Lerner S, Wang X, Ferrajoli A, Burger JA, Estrov Z, Wierda WG, Kantarjian HM, O'Brien S, Abruzzo LV, Keating MJ. Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality. Blood (ASH Annual Meeting Abstracts), 2012.
106. Köhrer S, Coffey G, Kim E, Rosin NY, Sinha U, Pandey A, Shehata M, Ulrich Jäger M, O'Brien SM, Wierda WG, Estrov Z, Thomas D, Kantarjian HM, Burger JA. Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 2012.
107. Rosin NY, Köehrer S, Kim E, O'Brien SM, Wierda WG, Thomas DA, Estrov Z, Kantarjian HM, Lannutti BJ, Burger JA. In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 2012.
108. Boumber Y, Thomas DA, Ravandi F, Rytting ME, Love MR, Lu H, Garris R, Cortes JE, O'Brien S, Burger JA, Kantarjian HM, Konopleva M. Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts), 2012.
109. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Borthakur G, Burger JA, Verstovsek S, Ferrajoli A, Wierda WG, Kornblau SM, Andreeff M, Garris R, Wang SA, Estrov Z, Cortes JE, O'Brien S. Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. Blood (ASH Annual Meeting Abstracts), 2012.
110. Daver N, Kantarjian HM, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, O'Brien SM, Ferrajoli A, Verstovsek S, Kadia TM, Jabbour EJ, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce SA, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood (ASH Annual Meeting Abstracts), 2012.
111. Bulian P, Shanafelt TD, Peppe C, Fegan C, Del Poeta G, Gaidano G, Rossi D, Baldini L, Cro L, Nuckel H, Burger JA, Gattei V. Prognostic Relevance of CD49d Expression On B Leukemic Cells in Chronic Lymphocytic Leukemia. Meta-Analysis of Published and unpublished Individual Data From 3146 Patients. Blood (ASH Annual Meeting Abstracts), 2012.
112. Ponader S, Balasubramanian S, Pham LV, Jun C, Archito TT, Wang M, O'Brien S, Wierda WG, Keating MJ, Ford RJ, Burger JA. Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,. Blood (ASH Annual Meeting Abstracts) 118, 2011.
113. Chen SS, Buggy JJ, Chang BY, Burger JA, Chiorazzi N. Btk Inhibitor, PCI-32765, Delays CLL Progression in a TCL1 Adoptive Transfer Model by Impairing Migration and Cell Proliferation. ASH Annual Meeting Abstracts 118, 2011.
114. O'Brien S, Burger JA, Blum KA, Furman RR. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. Blood (ASH Annual Meeting Abstracts) 118, 2011.
115. Hoellenriegel J, Zboralski D, Estrov Z, Wierda WG, Keating M, Kruschinski A, Burger JA. The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration. Blood (ASH Annual Meeting Abstracts) 118, 2011.
116. Ravandi F, Thomas DA, O'Brien S, Garris R, Faderl S, Shan J, Borthakur G, Burger JA, Ferrajoli A, Kebriaei P, Champlin R, Estrov Z, Wang SA, Jorgensen JL, Luthra R, Cortes JE, Kantarjian HM. Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy 118, 2011.
117. Alattar ML, Kantarjian HM, Jabbour E, Quintas-Cardama A, Burton EM, Borthakur G, Verstovsek S, Wierda WG, Konopleva M, Burger JA, O'Brien S, Cortes JE. Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP. Blood (ASH Annual Meeting Abstracts), 2011.
118. Tambaro FP, Garcia-Manero G, Faderl S, O'Brien S, Ferrajoli A, Burger JA, Trinh LX, Lerner S, Kantarjian HM, Keating MJ, Wierda WG. Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC). Blood (ASH Annual Meeting Abstracts) 118, 2011.
119. Evans E, Tester R, Aslanian S, Chaturvedi P, Mazdiyasni H, Ponader S, Tesar B, Sheets M, Nacht M, Stiede K, Witowski S, Lounsbury H, Petter R, Brown JR, Burger JA, Singh J, Westlin WF. Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies. Blood (ASH Annual Meeting Abstracts) 118, 2011.
120. Thomas DA, Kantarjian HM, Faderl S, Wierda W, Jabbour E, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad L, Romaguera JE, Garris R, Cortes JE, O'Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood (ASH Annual Meeting Abstracts) 118, 2011.
121. Liu-Dumlao T, Kantarjian HM, Quintas-Cardama A, Jabbour E, Burger JA, Alvarado Y, Burton EM, Trinh LX, Ravandi F, Ferrajoli A, O'Brien S, Cortes JE. Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML). Blood (ASH Annual Meeting Abstracts) 118, 2011.
122. Li P, Zhiming L, Harris D, Ferrajoli A, Wang Y, Hazan-Halevy I, Grgurevic S, Wierda G, Burger JA, O'Brien S, Faderl S, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription (STAT)-3 Induces Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Receptor-α Expression in Chronic Lymphocytic Leukemia (CLL) Cells. Blood (ASH Annual Meeting Abstracts) 118, 2011.
123. Daver N, Kantarjian HM, Garcia-Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Brandt M, Huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 118, 2011.
124. Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi V. A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL. Blood (ASH Annual Meeting Abstracts) 118, 2011.
125. Wierda WG, O'Brien S, Ferrajoli A, Koller CA, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Lerner S, Keating MJ. Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclophosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL. Blood (ASH Annual Meeting Abstracts) 118, 2011.
126. Pozadzides JV, Keating MJ, Wierda WG, O'Brien S, Burger JA, Jorgensen JL, Calin S, Wang SA, Lerner S, Ferrajoli A. Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy. Blood (ASH Annual Meeting Abstracts) 118, 2011.
127. Lee HJ, Kantarjian HM, Thomas DA, Faderl S, Koller C, Ferrajoli A, Jabbour E, Garris R, Kebriaei P, Champlin R, Borthakur G, Wierda WG, Burger JA, Cortes JE, O'Brien S, Ravandi F. Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 118, 2011.
128. Lee HJ, O'Brien S, Kantarjian HM, Ravandi F, Faderl S, Koller C, Konopleva M, Verstovsek S, T Kadia, Garcia-Manero G, Borthakur G, William G. Wierda, WG, Burger JA, Thomas DA, Cortes JE. Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy. Blood (ASH Annual Meeting Abstracts) 118, 2011.
129. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau SM, Andreeff M, Garris R, Cortes JE, O'Brien S. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. Blood (ASH Annual Meeting Abstracts) 118, 2011.
130. Kadia T, Delioukina ML, Kantarjian HM, Keating MJ, Wierda WG, Burger JA, Wieland S, Levitt D. A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 118, 2011.
131. Sivina M, Kreitman RJ, Peled A, Ravandi F, Burger JA. Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors. Blood (ASH Annual Meeting Abstracts) 118, 2011.
132. Fiorcari S, Brown WS, McIntyre BW, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Marasca R, Lannutti BJ, Estrov Z, Burger JA. The PI3 Kinase Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures. Blood (ASH Annual Meeting Abstracts) 118, 2011.
133. H Ghanem, H Kantarjian, G Garcia-Manero, F Ravandi, Faderl S, Cortes JE, Reyes A, O'Brien SM, G Borthakur, Kadia TM, Burger JA, Konopleva M, E Jabbour. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Journal of Clinical Oncology, 2011 ASCO Annual Meeting 29(15):6568, 2011.
134. Byrd C, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, O'Brien SM. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. Journal of Clinical Oncology, 2011 ASCO Annual Meeting 29(15 (Suppl)):6508, 2011.
135. Andritsos L, Byrd JC, Jones JA, Hewes B, Kipps TJ, Hsu FJ, Burger JA. Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116, 2010.
136. Ponader S, Buggy J, O'Brien S, Wierda WG, Keating M, Burger JA. Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo. Blood (ASH Annual Meeting Abstracts) 116, 2010.
137. Ravandi F, Jorgensen J, O'Brien S, Thomas DA, Faderl S, York S, Burger JA, Ferrajoli A, Pierce S, Keating M, Kantarjian H. Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia. Blood (ASH Annual Meeting Abstracts) 116, 2010.
138. Jabbour E, Kantarjian H, Cornelison AM, Kadia T, Welch MA, Abruzzo LV, Burger JA, Ferrajoli A, Garcia-Manero G, Cortes JE. Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML). Blood (ASH Annual Meeting Abstracts) 116, 2010.
139. Hoellenriegel J, Meadows SA, Wierda WG, Keating MJ, Lannutti B, Burger JA. Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurselike Cells (NLC), In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116, 2010.
140. Sivina M, Hartmann E, Boucas J, Keating MJ, Wierda WG, Herling M, Rosenwald A, Burger JA. Stroma-Induced TCL1 Expression In Chronic Lymphocytic Leukemia Cells Is Associated with Down Regulation of TCL1A-Targeting miRNAs. Blood (ASH Annual Meeting Abstracts) 116, 2010.
141. Burger JA, O'Brien S, Fowler N, Advani R, Sharman JP, Furman RR, Izumi R, Buggy J, Loury D, Hamdy A, Byrd JC, Blum CA.. The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies. Blood (ASH Annual Meeting Abstracts) 116, 2010.
142. Thomas DA, O'Brien S, Cortes JE, Faderl S, Wierda WG, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Burger JA, Garris R, Romaguera J, Hagemeister F, Kantarjian H.. Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab. Blood (ASH Annual Meeting Abstracts) 116, 2010.
143. Eghtedar A, Verstovsek S, Cortes JE, Estrov Z, Burger JA, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Newton R, Kantarjian H, Ravandi F.. Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML). Blood (ASH Annual Meeting Abstracts) 116, 2010.
144. Frenzel LP, Schulz A, Pallasch CP, Claus R, Ponader S, Burger JA, Hallek M, Plass C, Wendtner CM. Microenvironment Influences Expression of TOSO – a Novel NF-Kappa B Target Gene In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116, 2010.
145. Jabbour E, Garcia-Manero G, Ghanem HA, Ravandi F, Faderl S, Cortes JE, Reyes AS, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Kantarjian HM.. A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS. Blood (ASH Annual Meeting Abstracts) 116, 2010.
146. Hoellenriegel J, Coffey G, Sinha U, Pandey A, Wierda WG, Keating MJ, Burger JA. Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116, 2010.
147. Badoux X, Al-Ameri AM, O'Brien S, Wierda WG, Burger JA, Faderl S, Estrov Z, Lerner S, Keating M, Ferrajoli A. Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL. Blood (ASH Annual Meeting Abstracts) 116, 2010.
148. Parikh SA, Wierda WG, Badoux X, O'Brien SM, Ferrajoli A, Faderl S, Burger JA, Lerner S, Kantarjian H, Keating MJ. Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). J Clin Oncol (2010 ASCO Annual Meeting) 28(7), 2010.
149. Vigil CE, Kantarjian H, Thomas DA, O'Brien SM, Ravandi Kashani F, Koller, CA, Burger JA, Garris RS, Baccus MD, Faderl S. Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL). J Clin Oncol (2010 ASCO Annual Meeting) 28((15)), 2010.
150. Kurtova A, Sivina M, Quiroga M, Wierda W, Keating MJ, Burger JA. The Immunophenotype Signature CD49d+CD38+ Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells. Blood (ASH Annual Meeting Abstracts) 114(22):150-151, 2009.
151. Sivina M, Hartmann E, Krupnik D, LaPushin R, Keating M, Kipps T, Rosenwald A, Wierda W, Burger JA. CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment. Blood (ASH Annual Meeting Abstracts) 114(22):151, 2009.
152. Thomas D, Kantarjian H, Faderl S, Wierda W, Cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau S, Andreeff M, Garris R, Keating M, O'Brien S. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood (ASH Meeting Abstracts) 114(22):344-345, 2009.
153. Ravandi F, Kantarjian H, Thomas D, Faderl S, Jones D, Koller C, Dara S, Garris R, Kebriaei P, Champlin R Borthakur G, Wierda W, Burger JA, Cortes J, O'Brien S. Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 114(22):345, 2009.
154. Garcia-Manero G, Tambaro F, Bekele F, Jabbour E, Ravandi F, Yang H, Borthakur G, Kadia T, Cortes J, Faderl S, Konopleva M, Pierce S, Burger JA, Estrov Z, O'Brien S, Thomas D, Newsome W, Kantarjian H. Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 114(22):436, 2009.
155. Badoux X, Ramos C, Harris D, Li P, Liu Z, Burger JA, O'Brien S, Ferrajoli A, Keating M, Estrov Z. Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3. Blood (ASH Annual Meeting Abstracts) 114(22):511, 2009.
156. Badoux X, Keating M, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Abruzzo L, Wierda W. Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. Blood (ASH Annual Meeting Abstracts) 114(22):513-514, 2009.
157. Sivina M, Hartmann E, Keating M, Wierda W, Rosenwald A, Burger JA. Marrow Stromal Cells Induce TCL1 Expression in Chronic Lymphocytic Leukemia B Cells. Blood (ASH Annual Meeting Abstracts) 114(22):927, 2009.
158. Badoux X, Keating M, O'Brien S, Kadia T, Ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger JA, Wierda W. Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114(22):1332-1333, 2009.
159. Batty N, Badoux X, Keating M, Lerner M, O'Brien S, Ferrajoli A, Kadia T, Burger JA, Faderl S, Wierda W. Pretreatment Factors Associated with Second Malignancies Occurring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114(22):1339-1340, 2009.
160. Manshouri T, Estrov Z, Burger JA, Livun A, Zhang Y, Ma S, Gaikwad A, Harris D, Kantarjian H, Verstovsek S. Bone Marrow Stromal Cells Reverse Proapoptotic Effects of JAK2 Inhibitor Atiprimod in Cells Carrying the JAK2V617F mutation. Blood (ASH Annual Meeting Abstracts) 112, 2008.
161. Quiroga M, Kurtova A, Wierda W, Keating M, Burger JA. Inhibition of BCR Signaling Using the SYK Inhibitor R406 Antagonizes Migratory and Pro-Survival Responses in CLL Cells. Blood (ASH Annual Meeting Abstracts) 112, 2008.
162. Henderson J, O’Brien S, Wang X, Faderl S, Ferrajoli A, Garcia-Manero G, Tam C, Burger JA, Abruzzo L, Schlette E, Lerner S, Keating M, Wierda W. Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment. Blood (ASH Annual Meeting Abstracts) 112, 2008.
163. Wierda W, O’Brien S, Wang X, Faderl S, Ferrajoli A, Garcia-Manero G, Cortes J, Tam C, Burger JA, Abruzzo L, Schlette E, Lerner S, Keating M. Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy. Blood (ASH Annual Meeting Abstracts) 112, 2008.
164. Wierda W, O’Brien S, Faderl S, Ferrajoli A, Koller C, Estrov Z, Burger JA, Lerner S, Kantarjian H, Keating, M. CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p. Blood (ASH Annual Meeting Abstracts) 112, 2008.
165. Kurtova A, Tamayo A, Ford, Jr. R, Burger JA. Migratory Activity and Stromal Cell Adhesion of Mantle Cell Lymphoma Cells Can Be Diminished by Blocking of VLA-4 and CXCR4 Receptors. Blood (ASH Annual Meeting Abstracts) 112, 2008.
166. Ravandi F, Thomas D, Kantarjian H, Faderl S, Koller C, Dara S, Garris R, Kebriaei P, Borthakur G, Wierda W, Burger JA, Cortes J, O’Brien S. Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 112, 2008.
167. Borthakur G, Estrov Z, Garcia-Manero G, Williams B, Wathen J, Konopleva M, Burger JA, Ferrajoli A, George S, Kantarjian H. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood (ASH Annual Meeting Abstracts) 112, 2008.
168. Kurtova A, Quiroga M, Wierda W, Keating M, Burger JA. Standardizing Co-Culture Conditions Between Chronic Lymphocytic Leukemia Cells and Marrow Stromal Cells: Towards a Reliable and Reproducible System to Assess Cell Adhesion-Mediated Drug Resistance. Blood (ASH Annual Meeting Abstracts) 112, 2008.
169. Faderl S, Thomas D, Koller C, Ravandi F, Burger JA, O’Brien S, Dara S, Kantarjian H. Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts) 112, 2008.
170. Schmitt-Graeff A, Bertz H, Metzger M, Strahm B, Stein H, Burger JA. Analysis of Clinico-Pathologic Features and Stromal Cell-Derived Factor (SDF)-1/CXCR4 in Myeloid Sarcoma. Blood (ASH Annual Meeting Abstracts) 112, 2008.
171. Thomas D, Kantarjian H, Faderl S, Wierda W, Ferrajoli A, Burger JA, Cortes J, Koller C, Borthakur G, Estrov Z, Konopleva M, Ravandi F, Garcia- Manero G, O’Brien S. Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts) 112, 2008.
172. Cortes J, O'Brien S, Ferrajoli A, Borthakur G, Burger JA, Wierda W, Garcia-Manero G, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). 2008 ASCO Annual Meeting, 2008.
173. Cortes J,O’Brien S, Jabbour E, Ferrajoli A, Borthakur G, Burger JA, Wierda W, Garcia-Manero G, Thomas M, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). 2007 ASH Annual Meeting & Exposition, 2007.
174. Mattiuzzi G, Cortes J, Cassat J, Blamble D, Bekele B, Beran M, Borthakur G, Ravandi F, Burger JA, Kantarjian H. An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC). 2007 ASH Annual Meeting & Exposition, 2007.
175. Quintás-Cardama A, Kantarjian H, Ravandi F, Burger JA, Borthakur G, Cortes J. Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy. 2007 ASH Annual Meeting & Exposition, 2007.
176. Burger JA, M Niedermeier , Bürkle A, Hartmann E, Wierda W, Keating M, Rosenwald A. High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Co-Cultures and in Response to BCR Stimulation. 2007 ASH Annual Meeting & Exposition, 2007.
177. Alvarado Y, Kantarjian H, Faderl S, Burger JA,Borthakur G, O’Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). 2007 ASH Annual Meeting & Exposition, 2007.
178. Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger JA, Verstovsek S, Garcia-Manero G, Cortes J. Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2. 2007 ASH Annual Meeting & Exposition, 2007.
179. Jabbour E, Kantarjian H,Jones D, O’Brien S,Garcia-Manero G, Burger JA, Cortes J. Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs). 2007 ASH Annual Meeting & Exposition, 2007.
180. Wierda W, O’Brien S, Faderl S, Ferrajoli A, Garcia-Manero G, Burger JA, Schlette E, Abruzzo L, Lerner S, Keating M. Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL. 2007 ASH Annual Meeting & Exposition, 2007.
181. Faderl S, Thomas D, Gandhi V, Borthakur G, Huang X, Plunkett W, Burger JA, Cortes J, O’Brien S, Ravandi F, Bretz J, Kwari M, Kantarjian H. Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL). 2007 ASH Annual Meeting & Exposition, 2007.
182. Ravandi F, Faderl S, Thomas D, Burger JA, Koller C, Garcia-Manero G, Morris G, Torma R, Kantarjian H, Issa J. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. 2007 ASH Annual Meeting & Exposition, 2007.
183. Jain N, Kantarjian H, Fava C, Thomas D, Burger JA, Borthakur G, Pate O, Cortes J. Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib. 2007 ASH Annual Meeting & Exposition, 2007.
184. Quiroga M, Henneberg M, Niedermeier M, Burger JA. CD62L (L-Selectin), CXCR4, CD49d, and CD38 Contribute to Migration of Chronic Lymphocytic B Cells Beneath Marrow Stromal Cells. 2007 ASH Annual Meeting & Exposition, 2007. PMID: 19318683.
185. Niedermeier M, Rawluk J, Knight Z, Shokat K, Wierda W, Keating M, Burger JA. Importance of PI3 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B Cells and the Stromal Microenvironment: Therapeutic Implications. 2007 ASH Annual Meeting & Exposition, 2007.
186. Delmonte, Jr, J, Kantarjian H, Estey E, Ravandi F, Borthakur G, Burger JA, Pierce S, Cortes J. Single Center Experience with Philadelphia Chromosome-Positive Acute Myeloid Leukemia. 2007 ASH Annual Meeting & Exposition, 2007.
187. Tam C, Thomas D, Ravandi F, Richardson C, Borthakur G, Burger JA, Estey E, Kantarjian H, Verstovsek S. Phase II Evaluation of Sunitinib Malate, a Multi-Targeted Inhibitor of Receptor Tyrosine Kinases, in Patients with Myelofibrosis. 2007 ASH Annual Meeting & Exposition, 2007.
188. Ravandi F, Verstovsek S, Estrov Z, Burger JA, George S, Bivens, C, Cortes-Franco J, Garrett W, Newton R, Kantarjian, H. Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study. Blood (ASH Meeting Abstracts), 2006.
189. Burger JA, Borthakur G, Pierce S, Kantarjian H, Estey E. Reproducibility of diagnosis in patients with myelodysplastic syndrome. 2006 ASCO Annual Meeting Vol 24, No. 18S, 2006.
190. Bürkle A, Burger JA.. Overexpression of the CXCR5 Chemokine Receptor, and its ligand, B cell-activating chemokine-1 (BCA-1/CXCL13) in B cell chronic lymphocytic leukemia. Blood 106(11):824a Part 1, 2005.
191. Hartmann TN, Krome M, Burger JA.. B-cell receptor signaling enhances migration of B-cell chronic lymphocytic leukemia cells in response to the chemokine stromal cell-derived factor-1 (SDF-1/CXCL12). Blood 106(11):347a Part 1, 2005.
192. Bert T, Filegauf M, Pitako J, Burger JA, Abdelkarim M, Guo Y, Staege MS, Burdach S, Lubbert M.. Induction of GI Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: p53-Independent Upregulation of p21/WAF/CIPI1. Blood 104(11):2576a, 2004.
193. Bürkle A, Schmitt-Gräff A, Krome M, Behringer D, Burger JA.. Expression and function of the CXCR5 chemokine receptor on B lymphocytes from patients with B cell chronic lymphocytic leukemia and other B cell neoplasias. Supplement to The Hematology Journal, 9th Annual Congress of EHA, Geneva, 2004.
194. Spoo AC, Wierda WG, Burger JA.. The CXCR4 Score: A New Prognostic Marker in Acute Myelogenous Leukemia. Blood 104(11):1072a, 2004.
195. Berg T, Filegauf M, Pitako J, Burger JA, Abdelkarim M, Guo Y, Staege MS, Burdach S, Lübbert M.. Induction of G1 Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: p53-Independent Upregulation of p21/WAF/CIPI1. Blood 104(11):2576a, 2004.
196. Burger M, Hartmann T, Burger JA, Ingrid U. Schraufstatter.. KSHV-GPCR and CXCR2 Transforming Capacity and Angiogenic Responses Are Mediated through a JAK2-STAT3 Dependent Pathway. Blood 104(11), 2004.
197. Hartman T, Burger JA, Glodek A, Fujii N, Burger M.. CXCR4 and Integrin Signaling Lead to Higher Resistance to Chemotherapy Induced Apoptosis in Small Cell Lung Cancer (SCLC). Onkologie 27(Suppl.3):35, 2004.
198. Burger M, Hartmann T, Burger JA, Schraufstatter I.. KSHV-GPRC and CXCR2 Transforming Capacity and Angiogenic Responses are Mediated Through a JAK2-STAT3 Dependent Pathway. Onkologie 27(Suppl.3):164, 2004.
199. Zeiser R, Burger JA, Bley T, Windfuhr-Blum M, Schulte-Mönting J, Behringer D.. Immunocytology of the cerebral spinal fluid as compared to magnetic resonance imaging in the diagnosis of leptomeningeal metastasis-a retrospective analysis. Onkologie 26(Suppl 5):224, 2003.
200. Rawluk J, Burger M, Burger JA.. Signal transduction pathways of the Cxcr4 chemokine receptor for migration and apoptosis of chronic lymphocytic leukemia B-cells. Onkologie 26(Suppl 5):167, 2003.
201. Rawluk J, Burger M, Burger JA. Signal transduction pathways of the CXCR4 chemokine receptor for migration and apoptosis of chronic lymphocytic leukemia B cells. Blood 102(11):1576a, 2003.
202. Burger M, Hartmann T, Fujii N, Kipps TJ, Burger JA.. CXCR4 chemokine receptor antagonists inhibit activation, migration, and survival of chronic lymphocytic leukemia B cells in response to stromal cell-derived factor-1 (SDF-1/CXCL12). Blood 102(11):1585a, 2003.
203. Burger JA, Bürkle A, Behringer D.. The chemokine B cell-activating chemokine-1 (BCA-1/CXCL13) is a powerful chemoattractant for chronic lymphocytic leukemia B cells. Onkologie 25(Suppl 4):173, 2002.
204. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H.. Expression of functional CCR-and CXCR chemokine receptors in podocytes. J Am Soc Nephrol 13(Suppl S):349A, 2002.
205. Burger JA, Burkle A, Behringer D.. B cell chronic lymphocytic leukemia cells express functional CXCR5 chemokine receptors for the chemokine B cell-activating chemokine-1 (BCA-1/CXCL13). Blood 98(11):639a, 2001.
206. Burger JA, Tsukada N, Kipps TJ, Burger M.. CXCR4 chemokine receptors target small cell lung cancer metastasis to the bone marrow. Blood 98(11):1239a, 2001.

Book Chapters

1. Burger JA. The CLL cell microenvironment. In: Adv Exp Med Biol. Springer: New York, 25-45, 2013.
2. Burger JA and Sipkins DA. The bone marrow microenvironment and its impact in acute and chronic B cell malignancies. In: Bone Marrow Lymphoid Infiltrates -Diagnosis and Clinical Impact. Springer-Verlag: London, 2012.
3. Burger JA. Chronic Lymphocytic Leukemia (CLL): From Biology to Targeted Therapy. In: Treatment Strategies, Hematology. 1. Cambridge Research Center, 47-52, 2012.
4. Burger JA. Targeting CXCR4 in Chronic Lymphocytic Leukemia: Preclinical Rationale and Early Clinical Experience. In: Novel Developments in Stem Cell Mobilization. Springer: New York, 369-386, 2012.
5. Burger JA. Mechanisms of leukemia cell trafficking, homing, and tissue retention in chronic lymphocytic leukemia. In: Hematology Education, Program for the 16th Congress of the European Hematology Association. 1, 91-99, 2011.
6. Burger JA. Chronic Lymphocytic Leukemia (CLL). In: Hematology und Internistische Onkologie. 3. Das Rote Buch: Germany, 2006.

Letters to the Editor

1. Ponader S, Burger JA. Modeling the marrow stem cell niche in vitro: is proximity the key to reproduction?. Haematologica 95: e5, 2010.